Pfizer (PFE) Stock Price Drops Over 50% Since Pandemic Peak

AI Summary

Pfizer (PFE) has experienced a stock price decline of over 50% since its peak during the COVID-19 pandemic. This significant drop is attributed to market adjustments after expectations of ongoing vaccine needs did not materialize, leading to decreased investor confidence. Additionally, Pfizer faces challenges with upcoming patent expirations through 2028 and has struggled to develop new drugs to replace those losing patent protection. The company’s recent decision to acquire a competitor with a promising GLP-1 drug may impact future growth prospects.